Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Several case series (55, 56) and open-label trials (5760) suggest that the combination of a better glycemic control, improved metabolic parameters and bodyweight reductions achieved by exenatide treatment as monotherapy or as add-on to standard therapies may lead to improvements in liver biomarkers and hepatic fat reductions in patients with T2D
O.FarrS
Others notice minimal effects
As in Phase-I HSB, phosphocreatine was not detected in the plasma of Phase-II HSB
10.1186/s13073-017-0451-z 36 BenakisC.BreaD.CaballeroS.FaracoG.MooreJ.MurphyM.et al
doi:10.1128/AEM.02542-10 66
US$ 26.02
US$ 25.70
US$ 29.43
US$ 26.99
US$ 27.26
US$ 25.72
